Paraoxonase (PON1) activity in north west Indian Punjabis with coronary artery disease & type 2 diabetes mellitus

Indian Journal of Medical Research

Volumn 125, Issue 6, 2007, Pages 783-787

  Singh, Surjit ^a   Venketesh, S ^a   Verma, J S ^a,c   Verma, Minni ^a,b   Lellamma, C O ^a   Goel, R C ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

^c FORTIS HOSPITAL   (India)

Author keywords

Coronary artery disease; North western Indian Punjabis; Paraoxonase activity

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANALYSIS OF VARIANCE; ANGIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISCRIMINANT ANALYSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INDIA; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; RISK FACTOR; UNIVARIATE ANALYSIS;

ADULT; AGED; ANGIOGRAPHY; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIA; LIPID PEROXIDATION; MALE; MIDDLE AGED; RISK FACTORS;

EID: 34548411677     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ellsworth DL, Sholinsky P, Jaquish C, Fabritz RR, Manolo TA. Coronary heart disease. At the interface of molecular genetics and preventive medicine. Am J Prev Med 1999; 16: 122-33.
2. Durington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Bio 2001; 21: 473-80.
3. Macknes MI, Abbot C, Arrol S, Durington PN. The role of high density lipoprotein and lipid soluble antioxidant vitamins in inhibiting low density lipoprotein oxidation. Biochem J 1993; 294: 829-34.
4. Mackness MI, Durrangton PN, Mackness B. How high density lipoprotein protects against the effects of lipid peroxidation. Curr Opinion Lipidol 2000; 11: 383-8.
5. Mackness B, Durrington PN, Mackness MI. Lack of protection against oxidative modification of LDL by avian HDL. Biochem Biophys Res Commun 1998; 247: 443-6.
6. Shih DM, Gu L, Xia YR, Navab M, Ll WF, Hana S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-7.
7. Mutch E, Elaine PG, Williams FM. Inter-individual variations in enzymes controlling organophosphate toxicity in man. Hum Exp Toxicol 1992; 11: 1091-6.
8. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/aryesterase polymorphism. Am J Hum Genet 1983; 35: 1126-38.
9. Singh S, Verma N, Nain CK, Co L, Goel RC, Sharma BK. Paraoxonase polymorphism in north-western Indians. Int J Clin Pharmacol Ther 1998; 36: 545-8.
10. Servato M, Marian AJ. A variant of human paraoxonase/arylesterase ( HUMPONA) gene is a factor for coronary artery disease. J Clin Invest 1995; 96: 3005-8.
11. Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE. Polymorphisms in the human paraoxonase activity (PON1) promoter. Pharmacogenetics 2001; 11: 77-84.
12. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atherosclerosis 2002; 3 (suppl): 40-55.
13. Deakin SP, James RW. Genetics and environmental factors modulating serum concentrations and activities of antioxidant enzyme paraoxonase-1. Clin Sci 2004; 107: 435-47.
14. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2000; 21: 451-7.
15. Enas A, Yusuf S, Mehta JL. Prevalence of coronary artery disease in Asian Indians. Am J Cardiol 1992; 70: 945-9.
16. Singh S, Verma M, Nain CK, Leelamma CO, Goel RC. Paraoxonase (PON1) polymorphism and its relation with lipids in north-west Indian Punjabis. Indian J Med Res 1999; 110: 133-7.
17. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of ultracentrifuge. Clin Chem 1972; 18: 499-502.
18. Primo-Parmo SL, Sorensen RE, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of multi gene family. Genomics 1996; 33: 498-507.
19. Mackness MC, Mackness B, Durrington PN, Connely PW, Hegle RA. Paraoxonase: Biochemistry, genetics, relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.
20. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine of position 191, for respective A or B allozymes. Am J Hum Genetics 1993; 52: 598-608.
21. Wang X, Fan Z, Huang J, Su S, Yu Q, Zhao J, et al. Extensive association analysis between polymorphism of PON gene cluster with coronary heart disease in Chinese Han Population. Arteriosclerosis Thromb Vasc Biol 2003; 23: 328-34.
22. Lowlar DA, Day NMI, Gaunt TR, Hinks LJ, Briggs PJ, Kiessling, M, et al. The association of PON1 Q 192 R polymorphism with coronary heart disease: findings from British Women's heart and health cohort study and a metaanalysis. BMC Genet 2004; 5: 17.
23. Mc.Eleveen J, Mackness MI, Solley CM, Peard T, Warner S, Walker H. Distribution of paraoxon, hydrolyzing activity in the serum of patients after myocardial infarction. Clin Chem 1986; 32: 671-3.
24. Ayub A, Mackness MJ, Arrol S, Mackness B, Patel J, Durrington PN. Serum paroxonase after myocardial infarction. Arterioscle Thromb Vasc Biol 1999; 19: 330-5.
25. Jarvik GP, Rozek ZS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1 192 or PON1 55 genotype. Arterioscler Thromb Vasc Biol 2000; 20: 2441-7.
26. Mackness B, Durrington P, McElduf P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective study. Circulation 2003; 107: 2775-9.
27. Goeman AY, Gumushi S, Semiz E. Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease. Clin Cardiol 2004; 27: 426-30.
28. Mackness MI, Harty D, Bhatnagar D, Wincour PH, Arrol S, Ishola M, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-9.
29. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependant diabetes mellitus. Atherosclerosis 1998; 139: 341-9.
30. Kopporasch S, Pietzsch J, Kuhlissch E, Graessler T. Lack of association between serum paraoxonase 1 activities and increased oxidized low density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. J Endocrinol Metab 2003; 88: 1711-6.
31. Stozmen B, Delen Y F KG, Sozeman EY. Catalase and paroxonase in hypertensive type 2 diabetes mellitus: correlation with glycemic control? Clin Biochem 1999; 32: 423-7.
32. Ruiz J, Blanche H, James RW, Gavin MCB, Vaisse C, Charpentier G, et al. Gln Arg 192 polymorphisma of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869-72.
33. Odowara M, Tachi Y, Yamashita K. Paraoxonase polymorphism (Gln 192 Arg) is associated with coronary heart disease in Japanese non insulin dependent diabetes mellitus. J Clin Endcrinol Metab 1997; 82: 2257-60.
34. Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 1998; 141: 259-64.
35. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997; 17: 1067-73.
36. Mackness B, Mackness MI, Durrington PN, Arrol S, Evans AE, McMaster D, et al. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest 2000; 30: 4-10.